Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured News 3 Stocks Under $5 With Strong Analyst Upside PotentialAuthored by Chris Markoch. Originally Published: 2/24/2026. 
In Brief - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
While many investors are rotating out of speculative penny stocks, others still embrace their risk–reward profile. Stocks that trade for under $5 carry elevated risk: many are unprofitable, and some generate little to no revenue. In almost every case these are small-cap companies, a group that has been beaten up in recent years. Even with the Russell 2000 showing signs of recovery, that improvement hasn't been broad across the small-cap sector. That could change in 2026 if the economic outlook continues to improve, and money may flow back into more speculative names. As always, quality matters within any market segment. One way to filter for quality is to look for names with positive analyst sentiment. That's true of the three stocks below. Each lets investors establish a meaningful position with a modest outlay while still offering potential upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging market stocks are expected to be among the winners in 2026. That hasn't been the case so far for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. Based in Singapore, Grab operates a "super app" that combines technology, e-commerce and fintech services. One factor behind the stock's recent pullback is its proposed merger with Indonesian ride-hail competitor GoTo. The deal is not final and could be affected by significant legislative or regulatory changes in Indonesia that might limit the company's earnings potential in that market. Grab also came a bit light on the top line in its Q4 2025 earnings report. Some context helps: revenue rose 19% year-over-year, and the period marked the company's first full year of profitability. Analysts are forecasting roughly 120% earnings growth over the next 12 months. That partly explains why sentiment remains constructive. GRAB shares carry a consensus price target of $6.47, about 54% above the current price. High-Risk Biotech With Platform Potential Many penny stock investors look to the biotechnology sector for asymmetric returns. One name to watch is Vaxart Inc. (OTCMKTS: VXRT). The company meets the classic definition of a penny stock — at the time of writing its shares trade just above $0.60. VXRT has limited analyst coverage; the sole recent rating is a Buy with a $2 price target. It's not unusual for small biotechs to fly under the analyst radar. Vaxart is a clinical-stage company, meaning all of its candidates remain in clinical trials. The potential upside is straightforward: Vaxart is developing oral vaccines for influenza, norovirus and COVID-19. Beyond convenience and removing needle-related barriers, the company says its oral platform may induce a broader immune response and potentially broader protection, according to its investor materials. Institutional ownership in VXRT is modest, at about 18%. Still, in terms of dollar volume, reported inflows have outpaced outflows by nearly 10-to-1. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down roughly 33% so far in 2026, but a longer view is useful: over the past 12 months the stock is up more than 66%, suggesting this may be a normal pullback as investors shy away from companies that aren't yet profitable. In ThredUp's case, the caveat "yet" matters. The company runs an online consignment and thrift platform that's gaining traction with Gen Z — reflected in revenue trends. In its most recent quarter, revenue rose 12.5% year-over-year. ThredUp cites a GlobalData 2025 Market Survey projecting the U.S. secondhand market's gross merchandise value will grow at a compound annual growth rate (CAGR) of 9% through 2029. Institutional investors hold an impressive 89% of TDUP shares. Recent buying has outpaced selling about two-to-one by dollar volume and three-to-one by number of buyers versus sellers. That said, short interest is around 17%, which can add near-term volatility. The consensus price target from six analysts is $12.50, which would represent more than a 190% increase from the stock's level at the time of writing.
| 
